NEWARK, Calif., Aug. 6, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended June 30, 2014.
Second Quarter 2014 Summary
"Gralise and our recent acquisitions, CAMBIA and Lazanda, led the way to a strong quarter, doubling our net product sales over the same period last year. All four of our products showed prescription growth in Q2 compared to Q1 2014," said Jim Schoeneck, President and Chief Executive Officer of Depomed. "We believe the growth of our product revenues in Q2 and the integration of new products into our commercial organization demonstrate our ability to build a growth-oriented specialty pharmaceutical company focused on pain and central nervous system disorders. We are also thrilled to add Srini and Scott to our leadership team, increasing our depth and expertise in the pain and CNS markets. For the remainder of 2014, we are focused on growing product revenues, acquiring additional assets that will enhance our product portfolio and managing expenses to continue to operate at positive cash flow."
Accounting Treatment for the Sale of Type 2 Diabetes Royalty and Milestone Interests to PDLIn October 2013, Depomed sold interests in future royalty and milestone payments in the Type 2 diabetes therapeutic area to PDL Biopharma, Inc. (PDL) for $240.5 million. As a result of ongoing supply order obligations with respect to the underlying royalties, Depomed is accounting for this transaction under the debt accounting method. Although the royalty and milestone payments were sold to PDL, debt accounting requires the Company to continue to recognize the underlying royalties and milestones as revenue and record the proceeds of $240.5 million as a liability. As royalties and milestones are recognized under this arrangement, the liability is reduced and an implied non-cash interest expense is recognized.
During the three and six months ended June 30, 2014, Depomed recognized $33.3 million and $76.1 million, respectively, of non-cash revenues, $4.9 million and $10.3 million, respectively, in non-cash interest expense and $8.3 million and $20.1 million, respectively, in non-cash tax expense related to this arrangement.
Second Quarter 2014 Financial ResultsTotal revenues for the second quarter of 2014 increased to $67.7 million from $30.0 million for the second quarter of 2013. A summary of total revenues for the first quarter of 2014 as compared to the corresponding prior period is as follows:Three Months Ended Six Months Ended June 30,June 30,2014201320142013(Unaudited)(Unaudited)(Unaudited)(Unaudited)Product sales:Gralise
14,643Zipsor6,8225,55212,1658,592CAMBIA (1)4,958-9,582-Lazanda (1)1,354-2,034-Total product sales 28,24514,10649,75123,235Royalties:Glumetza US
27,481Other4309049251,697Total royalty revenue43015,09792529,178License and other revenue:Mallinckrodt
-Janssen---2,204Glumetza7607601,5201,520Other--1,000-Total license and other revenue5,76076017,5203,724Non-cash PDL royalty revenue
-Total revenues (GAAP Basis)$
Depomed acquired Lazanda in July 2013 and CAMBIA in December 2013.Selling, general and administrative expense was $32.6 million for the second quarter of 2014 as compared to $25.4 million for the second quarter of 2013. The increase in 2014 is primarily due to increased sales and marketing expenses associated with the Cambia and Lazanda® product acquisitions which occurred in the second half of 2013 and increased legal expense related to ongoing patent infringement litigation.
Research and development expense was $1.4 million for the second quarter of 2014 as compared to $1.4 million for the second quarter of 2013.
GAAP net income for the second quarter of 2014 was $12.7 million, or $0.21 per diluted share, compared to GAAP net income of $0.5 million, or $0.01 per diluted share for the second quarter of 2013. The increase in GAAP net income resulted primarily from increased product sales and the recognition of non-cash revenue relating to the royalties sold to PDL as described above under the caption "Accounting Treatment for the Sale of Type 2 Diabetes Royalties and Milestones to PDL."
Cash and marketable securities were $223.7 million as of June 30, 2014 as compared to $213.1 million as of March 31, 2014. The increase in cash and marketable securities in the second quarter of 2014 is primarily related to receipt of $15 million in milestone payments from Mallinckrodt during the second quarter of 2014.
2014 Financial Outlook Depomed is increasing its guidance for total revenues and GAAP earnings per share for full year 2014 and is reiterating its guidance for product sales, non-GAAP adjusted earnings per share and cash flow for full year 2014:
The increases in guidance regarding total revenues and GAAP earnings per share are entirely due to increased estimates of non-cash PDL royalty revenues resulting from net sales of Glumetza by Salix Pharmaceuticals during the first half of 2014.
Non-GAAP Financial MeasuresIn this press release, Depomed includes information about non-GAAP adjusted earnings per share, a non-GAAP financial measure, as a useful operating metric for the three and six month periods ended June 30, 2014 and its 2014 financial outlook. The Company believes that the presentation of this non-GAAP financial measure, when viewed with our results and projections under GAAP and the accompanying reconciliation, provides supplementary information to investors. The Company uses this non-GAAP measure in connection with its own planning and forecasting purposes and for measuring the Company's performance. This non-GAAP financial measure should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP adjusted earnings per share for the three and six month periods ended June 30, 2014 and guidance for the year ending December 31, 2014 are not based on any standardized methodology prescribed by GAAP and represents GAAP earnings per share adjusted to exclude (1) non-cash PDL royalty revenue, net of related costs, (2) non-cash interest expense on the liability related to the sale of future royalties and milestones to PDL, (3) amortization related to product acquisitions, and (4) stock-based compensation expense, and to adjust (5) the income tax provision to reflect the estimated amounts payable in cash. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.
The following table reconciles the Company's non-GAAP adjusted income/(loss) to GAAP net income for the three and six months ended June 30, 2014: RECONCILIATION OF GAAP NET INCOME TO NON-GAAP ADJUSTED EARNINGS/(LOSS)(in thousands, except per share amounts)Three Months EndedJune 30, 2014GAAP net income
12,746Non-cash PDL royalties, net of related costs(32,865)Non-cash interest expense on PDL liability4,903Amortization related to product acquisitions4,933Stock based compensation2,299Non-cash income tax adjustment8,300Non-GAAP adjusted earnings
316Non-GAAP adjusted earnings per share
0.01Six Months EndedJune 30, 2014GAAP net income
30,684Non-cash PDL royalties, net of related costs(75,210)Non-cash interest expense on PDL liability10,282Amortization related to product acquisitions9,489Stock based compensation4,170Non-cash income tax adjustment20,128Non-GAAP adjusted (loss)
(457)Non-GAAP adjusted (loss) per share
The following table reconciles the Company's non-GAAP adjusted earnings per share guidance to GAAP earnings per share guidance for the year ending December 31, 2014: RECONCILIATION OF GAAP EARNINGS PER SHARE TO NON-GAAP ADJUSTED EARNINGS PER SHAREGUIDANCE FOR THE YEAR ENDING DECEMBER 31, 2014GAAP earnings per share
0.36 - 0.51 Non-cash PDL royalties, net of related costs (1.26 - 1.46) Non-cash interest expense on PDL liability 0.29 - 0.33 Amortization related to product acquisitions 0.27 - 0.29 Stock based compensation 0.12 - 0.14 Non-cash income tax adjustment 0.22 - 0.35 Non-GAAP adjusted earnings per share
0.00 - 0.16 Conference CallDepomed will host a conference call today, Wednesday, August 6th, beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About DepomedDepomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology.
Additional information about Depomed may be found at www.depomed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the commercialization of Gralise, CAMBIA, Zipsor and Lazanda, Depomed's financial outlook for 2014 and expectations regarding financial results and potential business opportunities and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2014 and June 30, 2014. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
August J. Moretti
Canale Communications for Depomed
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (GAAP BASIS)(in thousands, except share and per share amounts)(Unaudited)Three Months Ended June 30,Six Months Ended June 30,2014201320142013Revenues:Product sales $
23,235Royalties 43015,09792529,178License and other revenue 5,76076017,5203,724Non-cash PDL royalty revenue33,297-76,081-Total revenues 67,73229,963144,27756,137Costs and expenses:Cost of sales 4,6751,6888,3773,172Research and development expense 1,3971,4123,4394,710Selling, general and administrative expense32,57325,36865,09051,331Amortization of intangible assets2,5429635,0811,924Total costs and expenses 41,18729,43181,98761,137Income (loss) from operations 26,54553262,290(5,000)Other income (expense)(596)6(1,196)(41)Non-cash interest expense on PDL liability(4,903)-(10,282)-Benefit from (provision for) income taxes (8,300)(60)(20,128)39Net income (loss)$
(5,002)Basic net income (loss) per share $
(0.09)Diluted net income (loss) per share $
(0.09)Basic shares58,105,90256,562,43357,827,43056,511,911Diluted shares60,430,45657,142,34360,258,44556,511,911 CONSOLIDATED CONDENSED BALANCE SHEETS (GAAP BASIS)(in thousands)June 30,December 31,20142013(Unaudited)(1)Cash, cash equivalents and marketable securities
276,017Accounts receivable17,27411,451Receivables from collaborative partners35,63510,824Inventories7,78210,145Property and equipment, net7,7318,340Intangible assets, net77,44082,521Deferred tax assets79,173103,202Prepaid and other assets7,3736,153Total assets
508,653Accounts payable and accrued liabilities
34,935Income taxes payable-61,875Deferred license revenue13,99515,516Liability related to sale of future royalties and milestones to PDL194,938233,981Other liabilities13,75213,666Contingent consideration liability12,19511,264Shareholders' equity179,326137,416Total liabilities and shareholders' equity
508,653(1) Derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.
|SOURCE Depomed, Inc.|
Copyright©2014 PR Newswire.
All rights reserved